Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
adagloxad simolenin (OBI 822) / OBI Pharma
2018-001438-16: Phase 3 Study of Adagloxad Simolenin (OBI-822)/OBI-821 Treatment for Breast Cancer Patients	Not yet recruiting	3	668	Europe	Adagloxad simolenin, OBI-821, Capecitabine, OBI-822, OBI-821, N/A, Powder for injection, Film-coated tablet	OBI Pharma, Inc., OBI Pharma, Inc.	Triple Negative Breast Cancer, Breast cancer, Diseases [C] - Cancer [C04]
NCT03562637 / 2018-001438-16: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC	Recruiting	3	668	Europe, US, RoW	adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment	OBI Pharma, Inc, OBI Pharma, Inc.	Triple Negative Breast Cancer	12/25	12/27